[Prevention of community-acquired respiratory syncytial virus infections in premature infants: cost-benefit evaluation in the Finistère Department].
Jacquemot
L
L
Catelin
C
C
Dobrzynski
M
M
de Parscau
L
L
Sizun
J
J
D000367:Age Factors; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001997:Bronchopulmonary Dysplasia / Q000150:complications; D017714:Community-Acquired Infections / Q000517:prevention & control; D003362:Cost-Benefit Analysis; D004311:Double-Blind Method; D005602:France; D006760:Hospitalization; D006801:Humans; D007116:Immunization, Passive; D007223:Infant; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000191:economics / Q000517:prevention & control*; D015337:Multicenter Studies as Topic; D000069455:Palivizumab; D010919:Placebos; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D018357:Respiratory Syncytial Virus Infections / Q000191:economics / Q000517:prevention & control*; D012189:Retrospective Studies; D012307:Risk Factors; D012621:Seasons; D013997:Time Factors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D010919:Placebos; D000069455:Palivizumab
Prévention des infections communautaires à virus respiratoire syncytial chez l'enfant né avant terme: évaluation coût/bénéfice dans le département du Finistère.